[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.232.99. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 1985

Levobunolol Compared With Timolol for the Long-term Control of Elevated Intraocular Pressure

Author Affiliations

From the Massachusetts Eye and Ear Infirmary Glaucoma Service, Boston (Dr Berson); the Letterman Army Medical Center Ophthalmology Clinic, San Francisco (Dr Cohen); the Colorado Springs (Colo) Medical Center (Dr Foerster); the University Hospitals of Cleveland (Dr Lass); and the University of California-Irvine and the Clinical Research Department, Allergan Pharmaceuticals, Inc, Irvine (Drs Novack and Duzman).

Arch Ophthalmol. 1985;103(3):379-382. doi:10.1001/archopht.1985.01050030075025
Abstract

• Levobunolol hydrochloride (0.5% and 1%) and timolol maleate (0.5%) are being compared in an ongoing, double-masked, randomized study of 141 patients with ocular hypertension or chronic open-angle glaucoma. Baseline intraocular pressure (IOP) in the three treatment groups ranged from 26 to 27 mm Hg. During the first 15 months of the study, the two drugs have not proved to be significantly different in ocular hypotensive efficacy, with overall mean IOP decreases of 6.8 to 7.6 mm Hg. In addition, the two concentrations of levobunolol have been equally effective in controlling IOP. Neither drug has been associated with any significant ocular side effects. Both drugs have produced significant decreases (five to ten beats per minute) in mean heart rate. The effect on mean blood pressure has been less pronounced: overall decreases have been less than 4 mm Hg for both systolic and diastolic blood pressure. The results of this ongoing study suggest that levobunolol is as effective and as safe as timolol for the long-term control of IOP.

×